These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17373169)

  • 41. Injectable poly-L: -lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne.
    Sadove R
    Aesthetic Plast Surg; 2009 Jan; 33(1):113-6. PubMed ID: 18923863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Canadian study of the use of poly-L-lactic acid dermal implant for the treatment of hill and valley acne scarring.
    Sapra S; Stewart JA; Mraud K; Schupp R
    Dermatol Surg; 2015 May; 41(5):587-94. PubMed ID: 25915626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Poly-L-lactic acid: a temporary filler for soft tissue augmentation.
    Woerle B; Hanke CW; Sattler G
    J Drugs Dermatol; 2004; 3(4):385-9. PubMed ID: 15303782
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of lipoatrophy and aging: volume deficits in the face.
    Coleman S; Saboeiro A; Sengelmann R
    Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs.
    Treacy PJ; Goldberg DJ
    Dermatol Surg; 2006 Jun; 32(6):804-8. PubMed ID: 16792645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Late-onset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: clinical findings and long-term follow-up.
    Alijotas-Reig J; Garcia-Gimenez V; Vilardell-Tarres M
    Dermatology; 2009; 219(4):303-8. PubMed ID: 19797889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV facial lipoatrophy: causes and treatment options.
    Jones D
    Dermatol Surg; 2005 Nov; 31(11 Pt 2):1519-29; discussion 1529. PubMed ID: 16416634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDA approves treatment for facial fat loss.
    AIDS Alert; 2004 Oct; 19(10):119-20. PubMed ID: 15484378
    [No Abstract]   [Full Text] [Related]  

  • 49. Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study.
    Narciso P; Bucciardini R; Tozzi V; Bellagamba R; Ivanovic J; Giulianelli M; Scevola S; Palummieri A; Fragola V; Massella M; Fracasso L; De Vita R; Pierro P; Del Maestro A; Mirra M; Weimer L
    AIDS Res Hum Retroviruses; 2009 Oct; 25(10):979-87. PubMed ID: 19795984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Poly-L-lactic acid: an overview.
    Simamora P; Chern W
    J Drugs Dermatol; 2006 May; 5(5):436-40. PubMed ID: 16703779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study.
    Guaraldi G; Orlando G; De Fazio D; De Lorenzi I; Rottino A; De Santis G; Pedone A; Spaggiari A; Baccarani A; Borghi V; Esposito R
    Antivir Ther; 2005; 10(6):753-9. PubMed ID: 16218175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Satisfying patient expectations with poly-L-lactic acid soft tissue augmentation.
    Vleggaar D; Fitzgerald R; Lorenc ZP
    J Drugs Dermatol; 2014 Apr; 13(4 Suppl):s40-3. PubMed ID: 24719077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients.
    Lafaurie M; Dolivo M; Porcher R; Rudant J; Madelaine I; Molina JM
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):393-8. PubMed ID: 15764955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances.
    Negredo E; Higueras C; Adell X; Martinez JC; Martinez E; Puig J; Fumaz CR; Muñoz-Moreno JA; Perez-Alvarez N; Videla S; Estany C; Cinquegrana D; Gonzalez-Mestre V; Clotet B
    AIDS Patient Care STDS; 2006 Dec; 20(12):829-37. PubMed ID: 17192148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Facial volume augmentation in 2014: overview of different filler options.
    Luebberding S; Alexiades-Armenakas M
    J Drugs Dermatol; 2013 Dec; 12(12):1339-44. PubMed ID: 24301234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The safety and efficacy of poly-L-lactic acid on sunken cheeks in Asians.
    Suh DH; Lee SJ; Kim SM; Lee JD; Kim HS
    J Cosmet Laser Ther; 2014 Aug; 16(4):180-4. PubMed ID: 24684570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.
    Loutfy MR; Raboud JM; Antoniou T; Kovacs C; Shen S; Halpenny R; Ellenor D; Ezekiel D; Zhao A; Beninger F
    AIDS; 2007 May; 21(9):1147-55. PubMed ID: 17502725
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The "skinny"on Sculptra: a practical primer to volumization with poly-L-lactic acid.
    Palm M; Chayavichitsilp P
    J Drugs Dermatol; 2012 Sep; 11(9):1046-52. PubMed ID: 23135646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy.
    Pignatti M; Pedone A; Baccarani A; Guaraldi G; Orlando G; Lombardi M; De Santis G
    Aesthetic Plast Surg; 2012 Feb; 36(1):180-5. PubMed ID: 21717261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.